Market revenue in 2023 | USD 7,377.6 million |
Market revenue in 2030 | USD 10,609.4 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Prostacyclin and prostacyclin analogs |
Fastest growing segment | SGC Stimulators |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pulmonary arterial hypertension market will help companies and investors design strategic landscapes.
prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.26% in 2023. Horizon Databook has segmented the Global pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global pulmonary arterial hypertension market , including forecasts for subscribers. This global databook contains high-level insights into Global pulmonary arterial hypertension market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account